Gestational Sulfadoxine-pyrimethamine and Azithromycin Treatment to Prevent Preterm Birth

Inclusion Criteria: * Signed informed consent * Age \>= 15 years * Ultrasound confirmed pregnancy * Quickening * Foetal age 14-26 gestation weeks * Maternal availability for follow-up during the entire study period Exclusion Criteria: * Known maternal tuberculosis, diabetes, kidney disease or liver disease * Any severe acute illness warranting hospital referral at enrollment visit * Mental disorder that may affect comprehension of the study or success of follow-up * Twin pregnancy * Pregnancy complications evident at enrollment visit (moderate to severe oedema, blood hemoglobin \[Hb\] concentration \< 50 g/l, systolic blood pressure \[BP\] \> 160 mmHg or diastolic BP \> 100 mmHg) * Prior receipt of azithromycin during this pregnancy * Receipt of sulfadoxine and pyrimethamine within 28 days of enrollment * Known allergy to drugs containing sulfonamides, macrolides or pyrimethamine * History of anaphylaxis * History of any serious allergic reaction to any substance, requiring emergency medical care * Concurrent participation in any other clinical trial